SOBRERA PHARMA RECEIVES PATENT APPROVAL IN THE USA
The United States Patent and Trademark Office (USPTO) has granted a new patent US 11,318,143 further strengthening the Company’s Intellectual property position and coverage for the Company’s [...]
Company Update – in Connection with the Annual General Meeting, June 10, 2021
Click below to read the presentation. Sobrera Update June 2021
Sobrera Pharma receives patent approval in Europe
Sobrera Pharma AB is pleased to announce the Decisions to Grant on the European patent 3582764 titled ’Treatment of Alcohol Use’ by the European Patent Office (EPO). The decision to grant on the [...]
Recruitment ongoing in the phase II study (COMB study).
Recruitment of patients to the phase II study (COMB study) is ongoing at the clinical study site in Gothenburg and in Stockholm. The study team is sharing information about the study including [...]
Sobrera Pharma and Recipharm in collaboration to advance a new treatment for patients with Alcohol Use Disorder
Swedish life science company, Sobrera Pharma, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development and [...]